Furthermore, a subset of NSCLC harbors inactivating mutations of both LKB1 and KEAP1/NRF2 and demonstrate a further aggressive clinical course with strong resistance to ICIs treatment [72]. The gene discussed is NFE2L2; the disease is non-small cell lung carcinoma.